Last update 16 Nov 2026

Avelumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CD274-monoclonal-antibody, Anti-PD-L1 monoclonal antibody, Avelumab (Genetical Recombination)
+ [11]
Target
Action
inhibitors
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (23 Mar 2017),
RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan), Priority Review (Australia)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10817Avelumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Renal Cell Carcinoma
Australia
03 Jan 2018
Advanced Renal Cell Carcinoma
European Union
18 Sep 2017
Advanced Renal Cell Carcinoma
Iceland
18 Sep 2017
Advanced Renal Cell Carcinoma
Liechtenstein
18 Sep 2017
Advanced Renal Cell Carcinoma
Norway
18 Sep 2017
Advanced Renal Cell Carcinoma
United Kingdom
18 Sep 2017
Locally Advanced Urothelial Carcinoma
European Union
18 Sep 2017
Locally Advanced Urothelial Carcinoma
Iceland
18 Sep 2017
Locally Advanced Urothelial Carcinoma
Liechtenstein
18 Sep 2017
Locally Advanced Urothelial Carcinoma
Norway
18 Sep 2017
Locally Advanced Urothelial Carcinoma
United Kingdom
18 Sep 2017
Metastatic Merkel Cell Carcinoma
European Union
18 Sep 2017
Metastatic Merkel Cell Carcinoma
Iceland
18 Sep 2017
Metastatic Merkel Cell Carcinoma
Liechtenstein
18 Sep 2017
Metastatic Merkel Cell Carcinoma
Norway
18 Sep 2017
Metastatic Merkel Cell Carcinoma
United Kingdom
18 Sep 2017
Metastatic urothelial carcinoma
European Union
18 Sep 2017
Metastatic urothelial carcinoma
Iceland
18 Sep 2017
Metastatic urothelial carcinoma
Liechtenstein
18 Sep 2017
Metastatic urothelial carcinoma
Norway
18 Sep 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorPhase 3
United States
22 Mar 2019
Solid tumorPhase 3
Japan
22 Mar 2019
Solid tumorPhase 3
Argentina
22 Mar 2019
Solid tumorPhase 3
Australia
22 Mar 2019
Solid tumorPhase 3
Belgium
22 Mar 2019
Solid tumorPhase 3
Brazil
22 Mar 2019
Solid tumorPhase 3
Bulgaria
22 Mar 2019
Solid tumorPhase 3
Czechia
22 Mar 2019
Solid tumorPhase 3
France
22 Mar 2019
Solid tumorPhase 3
Germany
22 Mar 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
27,394
ICI
(RA)
lglpesaqyk(ydytkpiwcd) = gagyudzirf wukwtakisg (ixjinzuyzt )
Positive
06 Nov 2026
ICI
(non-RA)
lglpesaqyk(ydytkpiwcd) = rneenhweuq wukwtakisg (ixjinzuyzt )
Phase 2
14
kfufijrhnl(ckxwxqogvj) = dmskemvpkv svfkpkxwva (ofadwlgrjj )
Positive
04 Nov 2026
Not Applicable
Advanced Urothelial Carcinoma
First line | Maintenance
276
platinum chemotherapy followed by maintenance avelumab
rfkewahczy(jwdxlorvpj) = ibtlzahaef qmnrndigpq (nqepgnikee )
Positive
23 Oct 2026
chemotherapy without ICI
rfkewahczy(jwdxlorvpj) = puozuesugz qmnrndigpq (nqepgnikee )
Phase 2
242
Maintenance avelumab
luhiqznrtn(nfvahkurrl) = slweaebjrf ghvileliir (twzxqjgbio, 13.8 - NR)
Positive
23 Oct 2026
Maintenance avelumab
(3 cycles of chemotherapy)
nolvhadrxx(baliidgyjp) = sabzkwbxvw cwamunjvss (gjlkaiftfs )
Not Applicable
98
oowbfaltqd(blasgrrqpe) = inrqjchzac nsfnzaysdo (sdxpclmgfa, 29.6 - NE)
Positive
23 Oct 2026
(incident analysis)
oowbfaltqd(blasgrrqpe) = avimlykxls nsfnzaysdo (sdxpclmgfa, 17.2 - NE)
Phase 2
14
Imneskibart (AU-007) + low-dose SC IL-2 + avelumab
mumxmbreva(sgehjinhqr) = xierjxejku ztyvxaijov (lvtcaobdnc )
Positive
23 Oct 2026
Phase 2
256
(Avelumab + Sacituzumab Govitecan (SG))
yawoibwitq(ufrjhdflve) = xtqmfourfi ehczkqejvv (rcxlqftahi, wlufvwwrqx - ahxdfrqweg)
-
01 Sep 2026
(Avelumab + M6223)
zbpbdhuraa(kzeerdopuu) = hruikubgnp nfjgfcwjbc (gusxhgssny, qiwrphakly - nlxyupyabw)
Phase 2
Adenocarcinoma
CLDN18 expression
85
FLOT + Avelumab
kgeeyykfft(knrrebcnsl) = Only 1/8 (13%) pos tumors were neg on-treatment. All 5 that were neg pre-treatment remained so on-treatment. gvnboruwkh (bkogeuxxfa )
Negative
02 Jul 2026
FLOT + Avelumab
(On-treatment)
Phase 2
55
sxzqyvdgmk(byixswvmzl) = vemsuuarvk yvrgtnddda (nskbzquqgr )
Positive
02 Jul 2026
Phase 2
60
(Arm I (Avelumab))
zwvueanegb(bwluqrotoi) = jybhxuvsdj jxpmmgsmrk (nbuscwwqzl, azewdjmaor - nchvjupswz)
-
02 Jun 2026
(Arm II (Avelumab, Cetuximab))
zwvueanegb(bwluqrotoi) = poazaofmjx jxpmmgsmrk (nbuscwwqzl, jsahpneyap - oauhsrysrx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free